Current Pipeline

Along with the immediate term development of the Company’s multispecifics for the treatment of SCLC and colorectal cancer, Imunexus will continue to develop its other multispecific antibody products that address a number of oncology and autoimmune diseases.

Imunexus’ pipeline contains potential treatments for lymphoblastic leukaemia, breast cancer, non-Hodgkin's lymphoma, ovarian cancer, ankylosing spondylitis, and extreme peanut anaphylaxis.

Six of these products are based on commercial monoclonal antibodies, one is based on a poorly performing advanced preclinical monoclonal antibody, and one is a proprietary non-antibody multispecific. Imunexus expects to continue to add potential products into its pipeline as appropriate.